• U0126: From P38 Biology to MEK1/2 Translation

  2026-10-09

  A translational perspective on how U0126 can help distinguish MEK/ERK signaling from the ROS–P38 mechanism reported in orofacial neuropathic pain, while clarifying evidence strength, model boundaries, and strategic research opportunities.

• Sorafenib Research Context: Cancer and EBOV

  2026-10-08

  A source-grounded overview of Sorafenib (BAY-43-9006) as a multikinase cancer biology research tool and its reported investigation as a host-directed antiviral candidate against Ebola virus. The evidence is compared across biochemical, cellular, animal-model, and preprint data, with emphasis on interpretation limits and translational boundaries.

• Anlotinib Hydrochloride: Evidence and Research Context

  2026-10-08

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with a biologically plausible anti-angiogenic rationale, but the supplied evidence spans different levels of reliability. This overview compares supplier-reported endothelial assay findings with a published case report in intra-abdominal desmoplastic small round cell tumor, explains conceptual applications in cancer research, and defines the limitations that prevent broad claims about efficacy, selectivity, or clinical translation.

• Multi-Omics Maps ARID1A-Linked Melanoma Resistance

  2026-10-07

  The reference study integrates transcriptomic, proteomic, phosphoproteomic, and network-level evidence to define how ARID1A loss reshapes early and persistent responses to BRAF/MAPK inhibition. Its findings identify PRKD1, JUN, and NCK1 as candidate resistance nodes while connecting signaling rewiring with reduced HLA-related expression and extracellular-matrix remodeling.

• Vemurafenib in Melanoma: Five Evidence Questions

  2026-10-07

  A source-grounded overview of Vemurafenib (PLX4032) covering its biological principle, evidence quality, resistance interpretation, research scope, and key limitations in melanoma studies.

• NVP-BGJ398 Phosphate: FGFR Evidence Review

  2026-10-06

  A source-grounded overview of NVP-BGJ398 phosphate, covering FGFR biology, oncology relevance, SLC26A2-related chondrodysplasia findings, evidence strength, and translational limitations.

• Dihydrotestosterone (DHT): Signaling and Evidence

  2026-10-06

  Dihydrotestosterone (DHT) is an endogenous androgen and androgen receptor agonist. Supplier-reported studies associate DHT exposure with EGFR, ERBB2, AKT, and ERK1/2 signaling changes in androgen receptor-positive bladder cancer cells, while mouse ALS findings remain preclinical and model-specific.

• SARS-CoV-2 N Condensation and GCG

  2026-10-05

  The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a molecular feature linked to viral replication. It reports that (-)-gallocatechin gallate disrupts N–RNA condensation and reduces viral replication in experimental models, while also highlighting important limits on how broadly these findings can be translated.

• Kinase Signaling Meets Condensate Biology

  2026-10-05

  A source-grounded framework for evaluating the CK2 and ERK8 inhibitor B7464 alongside emerging research on RNA-driven condensates, with clear boundaries between reported evidence, mechanistic hypotheses, and translational opportunity.

• Berberrubine and NF-κB Signaling in RPE Cells

  2026-10-04

  A 2006 Life Sciences study examined how berberrubine affects cytokine-induced IL-8 and MCP-1 production in ARPE-19 retinal pigment epithelial cells. Its main contribution was to connect reduced chemokine expression with suppressed NF-κB nuclear translocation, while leaving important questions about causality and in vivo relevance unresolved.

• H-89 and Wnt-Driven Bone Metabolism

  2026-10-03

  The 2024 EMBO Reports study links Wnt3a signaling with calcium–PKA–GFAT1 activity, O-GlcNAcylation, PDK1 stabilization, aerobic glycolysis, and osteoblast formation. H-89 is relevant as a pharmacological probe for testing the PKA component of that model, but the supplied evidence does not establish H-89-specific effects or prove that PKA is the only pathway involved. This overview separates reported findings from interpretation, compares evidence strength, and defines the limits of applying H-89 to bone, metabolism, proliferation, or apoptosis studies.

• RRP Restores Lipid Metabolism in Liver Ischemia

  2026-10-02

  The reference study identifies restoration of hepatic cholesterol handling as a central mechanism by which Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury. Its mouse and hepatocyte experiments connect AMPK activation with suppression of SCAP-SREBP2 cholesterol synthesis and enhancement of LXRα-dependent cholesterol efflux, providing a mechanistic framework for lipid-loading studies.

• Trametinib: MEK–ERK Control in Stem Cell Assays

  2026-10-01

  Trametinib (GSK1120212) provides a precise way to dissect MEK–ERK signaling, cell-cycle control, and cancer-cell phenotypes. This article develops a deeper assay strategy linking pathway inhibition with the APEX2–TERT regulatory findings reported in human embryonic stem cells.

• U0126-EtOH: Practical MEK1/2 Inhibition

  2026-10-01

  U0126-EtOH provides a focused way to test whether MEK1/2-driven ERK signaling contributes to neuronal injury, inflammation, or stress-associated cell death. This guide connects validated biochemical potency with practical cell-based workflows, controls, and troubleshooting strategies for reproducible pathway experiments.

• Angiotensin (1-7): Assay Design Beyond Mas

  2026-09-30

  Angiotensin (1-7) is more than a Mas receptor agonist: it is a mechanistic probe whose peptide length, concentration, and assay context can reshape biological interpretation. This guide connects PI3K/AKT and ERK signaling biology with new evidence on peptide-dependent spike–receptor binding and practical experimental design.

8130 records 3/542 page Previous Next 12345 下5页 Last page